News and Press Releases

Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site

6 May 2024 -- Minnesota, US, and Missouri, US -- Kindeva Drug Delivery, a global leader in drug-device combination products, today announced its investment in a second manufacturing line for...

Category: Drug Delivery, Manufacturing and Packing
Posted: May 6, 2024

Revolutionising Patient Care: ProPharma and PBL Launch Innovative Cell & Gene Therapy Manufacturing Device

First-of-its-kind Cell Factory Box streamlines production, making advanced treatments accessible and affordable 2 May 2024 -- Raleigh, North Carolina -- ProPharma, the leading global provider of regulatory, clinical and compliance services...

Category: BioManufacturing, Clinical Trials, Drug Discovery
Posted: May 2, 2024

107 West Hargett St. Raleigh, NC 27601

Kite to Present Comparison of Outcomes of Tecartus (brexucabtagene autoleucel) from the Pivotal ZUMA-2 Trial Versus the EBMT Registry of alloSCT Patients in Mantle Cell Lymphoma (MCL) at 50th EBMT 2024

Additional analysis demonstrates cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy In patients With large B-cell lymphoma In Italy 9 April 2024 -- Stockley Park, UK --...

Category: Biotechnology, Clinical Trials
Posted: April 12, 2024

2400 Broadway Santa Monica, CA 90404

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumour Biology in a Paired Biopsy Clinical Study

NUC-7738 reprogrammes cancer cell lipid metabolism to make tumours less aggressive and promote cancer cell death NUC-7738 alters ribosome biogenesis and the regulation of genes critical for cancer growth and...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: April 10, 2024

https://www.nucana.com/

University of Liverpool to Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical Study

The UK’s Medical Research Council is funding a 10-patient phase 1 study to deliver rapid personalised treatment for lung cancer patients 3 April 2024 -- Hampton, UK -- Touchlight, a...

Category: Biotechnology, Clinical Trials
Posted: April 3, 2024

Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

Nonacus launches test for comprehensive genomic profiling, integrated with bioinformatics and analysis software

2 April 2024 -- Birmingham, UK -- Genetic testing company, Nonacus, has launched GALEAS Tumor, a next generation sequencing (NGS) test that provides comprehensive genomic profiling of tumours, allowing clinicians...

Category: Biotechnology
Posted: April 2, 2024

Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham B32 1AF, United Kingdom

Touchlight Awarded Tender to Supply Enzymatic dbDNA to CPI’s RNA Centre of Excellence

28 March 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO enabling the development of genetic medicines with its doggybone DNA (dbDNA) technology and leaders in enzymatic DNA production, is...

Category: Biotechnology
Posted: March 28, 2024

Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

Recipharm attains major sustainability milestones

Approval of ambitious Greenhouse Gas emission reduction targets by SBTi Commitment to renewable electricity sourcing to 100.0% by 2024 and to 42.1% GHG emission reduction (Scope 1 and 2) by...

Category: Manufacturing and Packing
Posted: March 26, 2024

Gilbert To Officially Open New Development and GMP Manufacturing Facility

22 March 2024 -- Nottingham, UK -- UK-based contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions was joined by Oxford/AstraZeneca COVID-19 vaccine co-inventor Professor Dame Sarah Gilbert, biotech industry representatives and...

Category: BioManufacturing, Clinical Trials, Manufacturing and Packing
Posted: March 22, 2024

Albert Einstein Centre, Nottingham Science Park, Nottingham, UK, NG7 2TN

Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours

Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US...

Category: Biotechnology, Pharmaceutical
Posted: March 21, 2024

Am Klopferspitz 19, 82152 Planegg, Germany

ICR scientists seek new drugs to treat childhood cancer as part of global Cancer Grand Challenges team

6 March 2024 -- London, UK -- A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle...

Category: Clinical Trials, Pharmaceutical
Posted: March 6, 2024

123 Old Brompton Road London SW7 3RP

Global Clinical Trial Supply Leader partners with Pill Connect to deliver greater confidence in clinical trial outcomes

5 March 2024 -- Manchester, UK -- Pill Connect, the smart dosing device company, today announces its acceptance onto the leading CDMO’s (Contract development and manufacturing organisation) smart packaging supply...

Category: Clinical Trials, Drug Delivery, Logistics
Posted: March 5, 2024

125 Deansgate, Manchester, M2 3BY, UK

Informed Genomics Limited comments on launch of national BRCA gene testing programme to identify cancer risk early

7 February 2024 -- Birmingham, UK -- NHS England have launched a genetic testing programme targeting tens of thousands of people with Jewish ancestry who are more likely to carry...

Category: Biotechnology
Posted: February 7, 2024

Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham, B32 1AF

First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial

Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...

Category: Drug Discovery
Posted: February 7, 2024

C/ Natzaret, 115-117 Barcelona, Spain, 08035

Cellular Origins, a TTP Company, appoints Peter Crossley as Chief Operating Officer

Product and technology innovator will build team to further develop and deliver Cellular Origins’ products for cell and gene therapy manufacture at scale 25 January 2024 -- Cambridge, UK --...

Category: BioManufacturing
Posted: January 25, 2024

TTP Campus Cambridge Road Melbourn SG8 6HQ